ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Glioma cell-free DNA methylation marker for diagnosis and monitoring (2020)
Sabedot, Thais; Malta, Tathiane Maistro; Snyder, James; Nelson, Kevin; Wells, Michael; Carvalho, Ana de; Mukherjee, Abir; Chitale, Dhan; Mosella, Maritza Queiroz Salas ; Castro, Ana Valéria; Noushmehr, Houtan
Fonte: Clinical Cancer Research. Nome do evento: AACR Special Conference on Advances in Liquid Biopsies. Unidade: FMRP
Assuntos: BIOMARCADORES, METILAÇÃO DE DNA, GLIOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SABEDOT, Thais et al. Glioma cell-free DNA methylation marker for diagnosis and monitoring. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1557-3265.LiqBiop20-A10. Acesso em: 22 out. 2025. , 2020
APA
Sabedot, T., Malta, T. M., Snyder, J., Nelson, K., Wells, M., Carvalho, A. de, et al. (2020). Glioma cell-free DNA methylation marker for diagnosis and monitoring. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1158/1557-3265.LiqBiop20-A10
NLM
Sabedot T, Malta TM, Snyder J, Nelson K, Wells M, Carvalho A de, Mukherjee A, Chitale D, Mosella MQS, Castro AV, Noushmehr H. Glioma cell-free DNA methylation marker for diagnosis and monitoring [Internet]. Clinical Cancer Research. 2020 ; 26( 11):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.LiqBiop20-A10
Vancouver
Sabedot T, Malta TM, Snyder J, Nelson K, Wells M, Carvalho A de, Mukherjee A, Chitale D, Mosella MQS, Castro AV, Noushmehr H. Glioma cell-free DNA methylation marker for diagnosis and monitoring [Internet]. Clinical Cancer Research. 2020 ; 26( 11):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.LiqBiop20-A10
Trabalho de evento-resumo periodico
DNA methylation-based liquid biopsy detects primary and recurrent meningioma (2020)
Sabedot, Thais Sarraf; Malta, Tathiane M.; Snyder, James; Walbert, Tobias; Lee, Ian; Kalkanis, Steven; Castro, Ana Valéria; Noushmehr, Houtan
Fonte: Clinical Cancer Research. Nome do evento: AACR Special Conference on Advances in Liquid Biopsies. Unidade: FMRP
Assuntos: BIÓPSIA, METILAÇÃO DE DNA, MENINGIOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SABEDOT, Thais Sarraf et al. DNA methylation-based liquid biopsy detects primary and recurrent meningioma. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1557-3265.LiqBiop20-A12. Acesso em: 22 out. 2025. , 2020
APA
Sabedot, T. S., Malta, T. M., Snyder, J., Walbert, T., Lee, I., Kalkanis, S., et al. (2020). DNA methylation-based liquid biopsy detects primary and recurrent meningioma. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1158/1557-3265.LiqBiop20-A12
NLM
Sabedot TS, Malta TM, Snyder J, Walbert T, Lee I, Kalkanis S, Castro AV, Noushmehr H. DNA methylation-based liquid biopsy detects primary and recurrent meningioma [Internet]. Clinical Cancer Research. 2020 ; 26( 11):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.LiqBiop20-A12
Vancouver
Sabedot TS, Malta TM, Snyder J, Walbert T, Lee I, Kalkanis S, Castro AV, Noushmehr H. DNA methylation-based liquid biopsy detects primary and recurrent meningioma [Internet]. Clinical Cancer Research. 2020 ; 26( 11):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.LiqBiop20-A12
Trabalho de evento-resumo periodico
Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features (2020)
Wells, Michael; Asmaro, karam; Sabedot, Thais; Mosella, Maritza Queiroz Salas ; Malta, Tathiane; Nelson, Kevin; Snyder, James; Kalkanis, Steven; Castro, Ana Valéria; Noushmehr, Houtan
Fonte: Clinical Cancer Research. Nome do evento: AACR Special Conference on Advances in Liquid Biopsies. Unidade: FMRP
Assuntos: METILAÇÃO DE DNA, GLÂNDULA PITUITÁRIA, NEOPLASIAS, BIÓPSIA, GLIOMA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WELLS, Michael et al. Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1557-3265.LiqBiop20-A11. Acesso em: 22 out. 2025. , 2020
APA
Wells, M., Asmaro, karam, Sabedot, T., Mosella, M. Q. S., Malta, T., Nelson, K., et al. (2020). Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1158/1557-3265.LiqBiop20-A11
NLM
Wells M, Asmaro karam, Sabedot T, Mosella MQS, Malta T, Nelson K, Snyder J, Kalkanis S, Castro AV, Noushmehr H. Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features [Internet]. Clinical Cancer Research. 2020 ; 26( 11):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.LiqBiop20-A11
Vancouver
Wells M, Asmaro karam, Sabedot T, Mosella MQS, Malta T, Nelson K, Snyder J, Kalkanis S, Castro AV, Noushmehr H. Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features [Internet]. Clinical Cancer Research. 2020 ; 26( 11):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.LiqBiop20-A11
Trabalho de evento-resumo periodico
Pan-cancer transcription factor analyses identify ZNF217 as a novel driver in HGSOC (2019)
Nameki, Robbin; Fonseca, Marcos A. S.; Reddy, Jessica; Vavra, Kevin C.; Segato, Felipe; Corona, Rosario I.; Seo, Ji-Heui; Liu, Annie; Abbasi, Forough; Lin, Xianzhi; Karlan, Beth Y.; Freedman, Matthew L.; Gayther, Simon A.; Noushmehr, Houtan ; Lawrenson, Kate
Fonte: Clinical Cancer Research. Nome do evento: Biennial Ovarian Cancer Research Symposium. Unidade: FMRP
Assuntos: TRANSCRIÇÃO GÊNICA, NEOPLASIAS OVARIANAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NAMEKI, Robbin et al. Pan-cancer transcription factor analyses identify ZNF217 as a novel driver in HGSOC. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 22 out. 2025. , 2019
APA
Nameki, R., Fonseca, M. A. S., Reddy, J., Vavra, K. C., Segato, F., Corona, R. I., et al. (2019). Pan-cancer transcription factor analyses identify ZNF217 as a novel driver in HGSOC. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
NLM
Nameki R, Fonseca MAS, Reddy J, Vavra KC, Segato F, Corona RI, Seo J-H, Liu A, Abbasi F, Lin X, Karlan BY, Freedman ML, Gayther SA, Noushmehr H, Lawrenson K. Pan-cancer transcription factor analyses identify ZNF217 as a novel driver in HGSOC. Clinical Cancer Research. 2019 ; 25( 22):[citado 2025 out. 22 ]
Vancouver
Nameki R, Fonseca MAS, Reddy J, Vavra KC, Segato F, Corona RI, Seo J-H, Liu A, Abbasi F, Lin X, Karlan BY, Freedman ML, Gayther SA, Noushmehr H, Lawrenson K. Pan-cancer transcription factor analyses identify ZNF217 as a novel driver in HGSOC. Clinical Cancer Research. 2019 ; 25( 22):[citado 2025 out. 22 ]
Trabalho de evento-resumo periodico
Upregulation of IDO in bacterial vaginosis: role in HPV coinfection (2018)
Venancio, Paloma Almeida; Maria-Engler, Silvya Stuchi ; Consolaro, Marcia Edilaine Lopes; Villa, Luisa Lina; Derchain, Sophie Françoise Mauricette; Campa, Ana ; Discacciati, Michelle Garcia
Fonte: Clinical Cancer Research. Nome do evento: AACR International Conference on Translational Cancer Medicine. Unidades: FM, FCF
Assuntos: HPV, BACTÉRIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VENANCIO, Paloma Almeida et al. Upregulation of IDO in bacterial vaginosis: role in HPV coinfection. Clinical Cancer Research. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A46. Acesso em: 22 out. 2025. , 2018
APA
Venancio, P. A., Maria-Engler, S. S., Consolaro, M. E. L., Villa, L. L., Derchain, S. F. M., Campa, A., & Discacciati, M. G. (2018). Upregulation of IDO in bacterial vaginosis: role in HPV coinfection. Clinical Cancer Research. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://clincancerres.aacrjournals.org/content/24/1_Supplement/A46
NLM
Venancio PA, Maria-Engler SS, Consolaro MEL, Villa LL, Derchain SFM, Campa A, Discacciati MG. Upregulation of IDO in bacterial vaginosis: role in HPV coinfection [Internet]. Clinical Cancer Research. 2018 ; 24( 5):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A46
Vancouver
Venancio PA, Maria-Engler SS, Consolaro MEL, Villa LL, Derchain SFM, Campa A, Discacciati MG. Upregulation of IDO in bacterial vaginosis: role in HPV coinfection [Internet]. Clinical Cancer Research. 2018 ; 24( 5):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A46
Trabalho de evento-resumo periodico
Identification of new promising germline variants in melanoma-prone patients (2018)
Fidalgo, Felipe; Facure, Luciana; Barros, Bruna; Valieris, Renan; Torrezan, Giovana; Sá, Bianca Costa Soares de; Nóbrega, Amanda; Achatz, Maria Isabel; Duprat, João; Rosenberg, Carla ; Souza, Sandro; Krepischi, Ana Cristina Victorino ; Carraro, Dirce Maria
Fonte: Clinical Cancer Research. Nome do evento: AACR International Conference on Translational Cancer Medicine. Unidade: IB
Assuntos: MELANOMA, PREDISPOSIÇÃO GENÉTICA PARA DOENÇA, MUTAÇÃO GENÉTICA, BIOLOGIA MOLECULAR, GENÉTICA MÉDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FIDALGO, Felipe et al. Identification of new promising germline variants in melanoma-prone patients. Clinical Cancer Research. Philadelphia: Instituto de Biociências, Universidade de São Paulo. Disponível em: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A20. Acesso em: 22 out. 2025. , 2018
APA
Fidalgo, F., Facure, L., Barros, B., Valieris, R., Torrezan, G., Sá, B. C. S. de, et al. (2018). Identification of new promising germline variants in melanoma-prone patients. Clinical Cancer Research. Philadelphia: Instituto de Biociências, Universidade de São Paulo. Recuperado de http://clincancerres.aacrjournals.org/content/24/1_Supplement/A20
NLM
Fidalgo F, Facure L, Barros B, Valieris R, Torrezan G, Sá BCS de, Nóbrega A, Achatz MI, Duprat J, Rosenberg C, Souza S, Krepischi ACV, Carraro DM. Identification of new promising germline variants in melanoma-prone patients [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A20
Vancouver
Fidalgo F, Facure L, Barros B, Valieris R, Torrezan G, Sá BCS de, Nóbrega A, Achatz MI, Duprat J, Rosenberg C, Souza S, Krepischi ACV, Carraro DM. Identification of new promising germline variants in melanoma-prone patients [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A20
Trabalho de evento-resumo periodico
The association of caffeine, trigonelline, and chlorogenic acid, active components from coffee, enhances caffeine-induced cytotoxicity in hepatocellular carcinoma cells (2018)
Romualdo, Guilherme Ribeiro; Silva, Tereza Cristina da; Cogliati, Bruno ; Barbisan, Luis Fernando
Fonte: Clinical Cancer Research. Nome do evento: AACR International Conference. Unidade: FMVZ
Assuntos: CARCINOMA HEPATOCELULAR, CAFEÍNA, CITOTOXINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROMUALDO, Guilherme Ribeiro et al. The association of caffeine, trigonelline, and chlorogenic acid, active components from coffee, enhances caffeine-induced cytotoxicity in hepatocellular carcinoma cells. Clinical Cancer Research. Philadelphia: American Association for Cancer Research. Disponível em: https://doi.org/10.1158/1557-3265.TCM17-B73. Acesso em: 22 out. 2025. , 2018
APA
Romualdo, G. R., Silva, T. C. da, Cogliati, B., & Barbisan, L. F. (2018). The association of caffeine, trigonelline, and chlorogenic acid, active components from coffee, enhances caffeine-induced cytotoxicity in hepatocellular carcinoma cells. Clinical Cancer Research. Philadelphia: American Association for Cancer Research. doi:10.1158/1557-3265.TCM17-B73
NLM
Romualdo GR, Silva TC da, Cogliati B, Barbisan LF. The association of caffeine, trigonelline, and chlorogenic acid, active components from coffee, enhances caffeine-induced cytotoxicity in hepatocellular carcinoma cells [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.TCM17-B73
Vancouver
Romualdo GR, Silva TC da, Cogliati B, Barbisan LF. The association of caffeine, trigonelline, and chlorogenic acid, active components from coffee, enhances caffeine-induced cytotoxicity in hepatocellular carcinoma cells [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.TCM17-B73
Trabalho de evento-resumo periodico
Pyrimidobenzimidazoles as a potential new drug to treat human melanoma (2018)
Azevedo, Jéssica Gonçalves; Schultz, Iago Carvalho; Santos, Jacqueline Fraga de Souza; Maria-Engler, Silvya Stuchi ; Lenz, Guido; Wink, Márcia Rosângela
Fonte: Clinical Cancer Research. Nome do evento: AACR International Conference on Translational Cancer Medicine. Unidade: FCF
Assuntos: MELANOMA, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AZEVEDO, Jéssica Gonçalves et al. Pyrimidobenzimidazoles as a potential new drug to treat human melanoma. Clinical Cancer Research. Philadelphia: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: http://clincancerres.aacrjournals.org/content/24/1_Supplement/B34. Acesso em: 22 out. 2025. , 2018
APA
Azevedo, J. G., Schultz, I. C., Santos, J. F. de S., Maria-Engler, S. S., Lenz, G., & Wink, M. R. (2018). Pyrimidobenzimidazoles as a potential new drug to treat human melanoma. Clinical Cancer Research. Philadelphia: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Recuperado de http://clincancerres.aacrjournals.org/content/24/1_Supplement/B34
NLM
Azevedo JG, Schultz IC, Santos JF de S, Maria-Engler SS, Lenz G, Wink MR. Pyrimidobenzimidazoles as a potential new drug to treat human melanoma [Internet]. Clinical Cancer Research. 2018 ; 24( 5):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/B34
Vancouver
Azevedo JG, Schultz IC, Santos JF de S, Maria-Engler SS, Lenz G, Wink MR. Pyrimidobenzimidazoles as a potential new drug to treat human melanoma [Internet]. Clinical Cancer Research. 2018 ; 24( 5):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/B34
Trabalho de evento-resumo periodico
Epigenetic mechanisms in liver tumors: gene expression analysis of epigenetic machinery in hepatoblastomas (2018)
Rivas, Maria; Costa, Cecília da; Toledo, Silvia; Cypriano, Monica; Caires, Luiz; Goulart, Ernesto ; Carraro, Dirce; Werneck, Isabela; Rosenberg, Carla ; Zatz, Mayana ; Krepischi, Ana Cristina Victorino
Fonte: Clinical Cancer Research. Nome do evento: AACR International Conference on Translational Cancer Medicine. Unidade: IB
Assuntos: NEOPLASIAS HEPÁTICAS, CARCINOGÊNESE, EPIGÊNESE GENÉTICA, EXPRESSÃO GÊNICA, CRIANÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIVAS, Maria et al. Epigenetic mechanisms in liver tumors: gene expression analysis of epigenetic machinery in hepatoblastomas. Clinical Cancer Research. Philadelphia: Instituto de Biociências, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1557-3265.TCM17-A10. Acesso em: 22 out. 2025. , 2018
APA
Rivas, M., Costa, C. da, Toledo, S., Cypriano, M., Caires, L., Goulart, E., et al. (2018). Epigenetic mechanisms in liver tumors: gene expression analysis of epigenetic machinery in hepatoblastomas. Clinical Cancer Research. Philadelphia: Instituto de Biociências, Universidade de São Paulo. doi:10.1158/1557-3265.TCM17-A10
NLM
Rivas M, Costa C da, Toledo S, Cypriano M, Caires L, Goulart E, Carraro D, Werneck I, Rosenberg C, Zatz M, Krepischi ACV. Epigenetic mechanisms in liver tumors: gene expression analysis of epigenetic machinery in hepatoblastomas [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.TCM17-A10
Vancouver
Rivas M, Costa C da, Toledo S, Cypriano M, Caires L, Goulart E, Carraro D, Werneck I, Rosenberg C, Zatz M, Krepischi ACV. Epigenetic mechanisms in liver tumors: gene expression analysis of epigenetic machinery in hepatoblastomas [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1557-3265.TCM17-A10
Trabalho de evento-resumo periodico
Insights into the somatic mutation burden of hepatoblastomas using whole exome sequencing (2018)
Aguiar, Talita; Rodrigues, Tatiane; Costa, Cecy Carlucci; Werneck, Isabela; Cypriano, Monica; Toledo, Silvia Regina Caminada de; Souza, Jorge Estefano Santana de; Tojal, Israel; Carraro, Dirce M; Rosenberg, Carla ; Krepischi, Ana Cristina Victorino
Fonte: Clinical Cancer Research. Nome do evento: AACR International Conference on Translational Cancer Medicine. Unidade: IB
Assuntos: NEOPLASIAS HEPÁTICAS, IMUNOHISTOQUÍMICA, MUTAÇÃO GENÉTICA, EXPRESSÃO GÊNICA, CARCINOGÊNESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AGUIAR, Talita et al. Insights into the somatic mutation burden of hepatoblastomas using whole exome sequencing. Clinical Cancer Research. Philadelphia: Instituto de Biociências, Universidade de São Paulo. Disponível em: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A18.article-info. Acesso em: 22 out. 2025. , 2018
APA
Aguiar, T., Rodrigues, T., Costa, C. C., Werneck, I., Cypriano, M., Toledo, S. R. C. de, et al. (2018). Insights into the somatic mutation burden of hepatoblastomas using whole exome sequencing. Clinical Cancer Research. Philadelphia: Instituto de Biociências, Universidade de São Paulo. Recuperado de http://clincancerres.aacrjournals.org/content/24/1_Supplement/A18.article-info
NLM
Aguiar T, Rodrigues T, Costa CC, Werneck I, Cypriano M, Toledo SRC de, Souza JES de, Tojal I, Carraro DM, Rosenberg C, Krepischi ACV. Insights into the somatic mutation burden of hepatoblastomas using whole exome sequencing [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A18.article-info
Vancouver
Aguiar T, Rodrigues T, Costa CC, Werneck I, Cypriano M, Toledo SRC de, Souza JES de, Tojal I, Carraro DM, Rosenberg C, Krepischi ACV. Insights into the somatic mutation burden of hepatoblastomas using whole exome sequencing [Internet]. Clinical Cancer Research. 2018 ; 24( 1):[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/24/1_Supplement/A18.article-info
Artigo de periodico
A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice (2016)
Tran, Thi; Dransart, Estelle; Gey, Alain; Merillon, Nathalie; Lone, Yu Chun; Godefroy, Sylvie; Sibley, Craig; Ferreira, Luís Carlos de Souza ; Medioni, Jacques; Oudard, Stephane; Johannes, Ludger; Tartour, Eric
Fonte: Clinical Cancer Research. Unidade: ICB
Assuntos: MICROBIOLOGIA, CÉLULAS DENDRÍTICAS, ORGANISMOS GENETICAMENTE MODIFICADOS, CAMUNDONGOS, VACINAS, NEOPLASIAS MAMÁRIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TRAN, Thi et al. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice. Clinical Cancer Research, v. 16, n. 22, p. 4133-4144, 2016Tradução . . Disponível em: https://doi.org/10.1158/1078-0432.CCR-16-0044. Acesso em: 22 out. 2025.
APA
Tran, T., Dransart, E., Gey, A., Merillon, N., Lone, Y. C., Godefroy, S., et al. (2016). A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice. Clinical Cancer Research, 16( 22), 4133-4144. doi:10.1158/1078-0432.CCR-16-0044
NLM
Tran T, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC de S, Medioni J, Oudard S, Johannes L, Tartour E. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice [Internet]. Clinical Cancer Research. 2016 ; 16( 22): 4133-4144.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.CCR-16-0044
Vancouver
Tran T, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC de S, Medioni J, Oudard S, Johannes L, Tartour E. A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu–expressing tumor in HLA-A2 transgenic mice [Internet]. Clinical Cancer Research. 2016 ; 16( 22): 4133-4144.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.CCR-16-0044
Artigo de periodico
Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups (2012)
Gadji, Macoura; Awe, Julius Adebayo; Rodrigues, Prerana; Kumar, Rajat; Houston, Donald S.; Klewes, Ludger; Dièye, Tandakha Ndiaye; Rego, Eduardo Magalhães; Passetto, Roberto Falcão; Oliveira, Fábio Morato de; Mai, Sabine
Fonte: Clinical Cancer Research. Unidade: FMRP
Assuntos: LEUCEMIA MIELOIDE AGUDA, MEDULA ÓSSEA, NÚCLEO CELULAR, ESTUDOS DE COORTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GADJI, Macoura et al. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clinical Cancer Research, v. 18, n. 12, p. 3293-3304, 2012Tradução . . Disponível em: https://doi.org/10.1158/1078-0432.CCR-12-0087. Acesso em: 22 out. 2025.
APA
Gadji, M., Awe, J. A., Rodrigues, P., Kumar, R., Houston, D. S., Klewes, L., et al. (2012). Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clinical Cancer Research, 18( 12), 3293-3304. doi:10.1158/1078-0432.CCR-12-0087
NLM
Gadji M, Awe JA, Rodrigues P, Kumar R, Houston DS, Klewes L, Dièye TN, Rego EM, Passetto RF, Oliveira FM de, Mai S. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups [Internet]. Clinical Cancer Research. 2012 ; 18( 12): 3293-3304.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.CCR-12-0087
Vancouver
Gadji M, Awe JA, Rodrigues P, Kumar R, Houston DS, Klewes L, Dièye TN, Rego EM, Passetto RF, Oliveira FM de, Mai S. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups [Internet]. Clinical Cancer Research. 2012 ; 18( 12): 3293-3304.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.CCR-12-0087
Artigo de periodico
HPV16 tumor associated macrophages suppress antitumor T cell responses (2009)
Lepique, Ana Paula ; Daghastanli, Katia Regina Perez; Cuccovia, Iolanda Midea ; Villa, Luisa Lina
Fonte: Clinical Cancer Research. Unidade: IQ
Assuntos: MACRÓFAGOS, PAPILLOMAVIRUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEPIQUE, Ana Paula et al. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clinical Cancer Research, v. 15, n. 13, p. 4391-4400, 2009Tradução . . Disponível em: http://clincancerres.aacrjournals.org/content/15/13/4391.full.pdf+html. Acesso em: 22 out. 2025.
APA
Lepique, A. P., Daghastanli, K. R. P., Cuccovia, I. M., & Villa, L. L. (2009). HPV16 tumor associated macrophages suppress antitumor T cell responses. Clinical Cancer Research, 15( 13), 4391-4400. Recuperado de http://clincancerres.aacrjournals.org/content/15/13/4391.full.pdf+html
NLM
Lepique AP, Daghastanli KRP, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses [Internet]. Clinical Cancer Research. 2009 ; 15( 13): 4391-4400.[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/15/13/4391.full.pdf+html
Vancouver
Lepique AP, Daghastanli KRP, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses [Internet]. Clinical Cancer Research. 2009 ; 15( 13): 4391-4400.[citado 2025 out. 22 ] Available from: http://clincancerres.aacrjournals.org/content/15/13/4391.full.pdf+html
Artigo de periodico
Serpin Peptidase Inhibitor Clade A Member 1 as a Potential Marker for malignancy in Insulinomas (2007)
Sá, Sandra Valéria de; Corrêa-Giannella, Maria Lúcia; Machado, Márcio Carlos; Krogh, Karin; Almeida, Madson Queiroz de; Pereira, Maria Adelaide Albergaria; Siqueira, Sheila Aparecida Coelho; Patzina, Rosely Antunes; Ibuki, Felícia Satie; Sogayar, Mari Cleide ; Machado, Marcel Cerqueira César; Giannella-Neto, Daniel; Sogayar, Mari Cleide
Fonte: Clinical Cancer Research. Unidades: FM, IQ
Assuntos: BIOMARCADORES, NEOPLASIAS PANCREÁTICAS (DIAGNÓSTICO), METÁSTASE NEOPLÁSICA (DIAGNÓSTICO), IMUNOHISTOQUÍMICA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SÁ, Sandra Valéria de et al. Serpin Peptidase Inhibitor Clade A Member 1 as a Potential Marker for malignancy in Insulinomas. Clinical Cancer Research, v. 13, n. 18, p. 5322-5330, 2007Tradução . . Disponível em: https://doi.org/10.1158/1078-0432.ccr-06-1477. Acesso em: 22 out. 2025.
APA
Sá, S. V. de, Corrêa-Giannella, M. L., Machado, M. C., Krogh, K., Almeida, M. Q. de, Pereira, M. A. A., et al. (2007). Serpin Peptidase Inhibitor Clade A Member 1 as a Potential Marker for malignancy in Insulinomas. Clinical Cancer Research, 13( 18), 5322-5330. doi:10.1158/1078-0432.ccr-06-1477
NLM
Sá SV de, Corrêa-Giannella ML, Machado MC, Krogh K, Almeida MQ de, Pereira MAA, Siqueira SAC, Patzina RA, Ibuki FS, Sogayar MC, Machado MCC, Giannella-Neto D, Sogayar MC. Serpin Peptidase Inhibitor Clade A Member 1 as a Potential Marker for malignancy in Insulinomas [Internet]. Clinical Cancer Research. 2007 ; 13( 18): 5322-5330.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.ccr-06-1477
Vancouver
Sá SV de, Corrêa-Giannella ML, Machado MC, Krogh K, Almeida MQ de, Pereira MAA, Siqueira SAC, Patzina RA, Ibuki FS, Sogayar MC, Machado MCC, Giannella-Neto D, Sogayar MC. Serpin Peptidase Inhibitor Clade A Member 1 as a Potential Marker for malignancy in Insulinomas [Internet]. Clinical Cancer Research. 2007 ; 13( 18): 5322-5330.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.ccr-06-1477
Artigo de periodico-carta/editorial
Circulating matrix metalloproteinase-9 levels as a biomarker of disease [Carta] (2005)
Gerlach, Raquel Fernanda; Tanus-Santos, José Eduardo
Fonte: Clinical Cancer Research. Unidades: FMRP, FORP
Assuntos: BIOMARCADORES, NEOPLASIAS, METALOPROTEINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GERLACH, Raquel Fernanda e TANUS-SANTOS, José Eduardo. Circulating matrix metalloproteinase-9 levels as a biomarker of disease [Carta]. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 22 out. 2025. , 2005
APA
Gerlach, R. F., & Tanus-Santos, J. E. (2005). Circulating matrix metalloproteinase-9 levels as a biomarker of disease [Carta]. Clinical Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
NLM
Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinase-9 levels as a biomarker of disease [Carta]. Clinical Cancer Research. 2005 ; 11 8887-8888.[citado 2025 out. 22 ]
Vancouver
Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinase-9 levels as a biomarker of disease [Carta]. Clinical Cancer Research. 2005 ; 11 8887-8888.[citado 2025 out. 22 ]
Artigo de periodico
Gene expression profile associated with response to doxorubicin-based therapy in breast cancer (2005)
Folgueira, Maria Aparecida Azevedo Koike ; Carraro, Dirce Maria; Brentani, Helena; Patra, D. F. D.; Barbosa, E. M.; Netto, M. M.; Caldeira, J. R. F.; Katayama, Maria Lucia Hirata; Soares, F. A.; Reis, L. F. L.; Kaiano, Jane Haruko Lima; Camargo, L. P.; Vêncio, Ricardo Zorzetto Nicoliello ; Snitcovsky, Igor Moyses Longo; Makdissi, Fabiana Baroni Alves; Silva, Paulo J. S. ; Goes, João Carlos Guedes Sampaio; Brentani, Maria Mitzi
Fonte: Clinical Cancer Research. Unidades: FM, IME
Assunto: NEOPLASIAS MAMÁRIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FOLGUEIRA, Maria Aparecida Azevedo Koike et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clinical Cancer Research, v. 11, n. 20, p. 7434-7443, 2005Tradução . . Disponível em: https://doi.org/10.1158/1078-0432.CCR-04-0548. Acesso em: 22 out. 2025.
APA
Folgueira, M. A. A. K., Carraro, D. M., Brentani, H., Patra, D. F. D., Barbosa, E. M., Netto, M. M., et al. (2005). Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clinical Cancer Research, 11( 20), 7434-7443. doi:10.1158/1078-0432.CCR-04-0548
NLM
Folgueira MAAK, Carraro DM, Brentani H, Patra DFD, Barbosa EM, Netto MM, Caldeira JRF, Katayama MLH, Soares FA, Reis LFL, Kaiano JHL, Camargo LP, Vêncio RZN, Snitcovsky IML, Makdissi FBA, Silva PJS, Goes JCGS, Brentani MM. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer [Internet]. Clinical Cancer Research. 2005 ; 11( 20): 7434-7443.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.CCR-04-0548
Vancouver
Folgueira MAAK, Carraro DM, Brentani H, Patra DFD, Barbosa EM, Netto MM, Caldeira JRF, Katayama MLH, Soares FA, Reis LFL, Kaiano JHL, Camargo LP, Vêncio RZN, Snitcovsky IML, Makdissi FBA, Silva PJS, Goes JCGS, Brentani MM. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer [Internet]. Clinical Cancer Research. 2005 ; 11( 20): 7434-7443.[citado 2025 out. 22 ] Available from: https://doi.org/10.1158/1078-0432.CCR-04-0548
Trabalho de evento-resumo periodico
Use of a cholesterol-rich emulsion that to low-density lipoprotein receptors as carrier for paclitaxel (2001)
Rodrigues, Daniella Goulart; Covollan, C. C.; Coradi, S.; Barboza, R.; Maranhão, Raul Cavalcante
Fonte: Clinical Cancer Research. Nome do evento: AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics. Unidade: FCF
Assuntos: ANTINEOPLÁSICOS (ESTUDO CLÍNICO), NEOPLASIAS (TERAPIA), QUIMIOTERAPIA, QUIMIOTERÁPICOS, LIPÍDEOS (FISIOLOGIA), FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RODRIGUES, Daniella Goulart et al. Use of a cholesterol-rich emulsion that to low-density lipoprotein receptors as carrier for paclitaxel. Clinical Cancer Research. Birmingham: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 22 out. 2025. , 2001
APA
Rodrigues, D. G., Covollan, C. C., Coradi, S., Barboza, R., & Maranhão, R. C. (2001). Use of a cholesterol-rich emulsion that to low-density lipoprotein receptors as carrier for paclitaxel. Clinical Cancer Research. Birmingham: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Rodrigues DG, Covollan CC, Coradi S, Barboza R, Maranhão RC. Use of a cholesterol-rich emulsion that to low-density lipoprotein receptors as carrier for paclitaxel. Clinical Cancer Research. 2001 ; 7( 11): 3675s res. 111.[citado 2025 out. 22 ]
Vancouver
Rodrigues DG, Covollan CC, Coradi S, Barboza R, Maranhão RC. Use of a cholesterol-rich emulsion that to low-density lipoprotein receptors as carrier for paclitaxel. Clinical Cancer Research. 2001 ; 7( 11): 3675s res. 111.[citado 2025 out. 22 ]
Artigo de periodico
Expression of a novel factor, com1, in early tumor progression of breast cancer (2000)
Ree, Anne Hansen; Pacheco, Mercia Medeiros; Tvermyr, Marianne; Fodstad, Oystein; Brentani, Maria Mitzi
Fonte: Clinical Cancer Research. Unidade: FM
Assuntos: ONCOLOGIA, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REE, Anne Hansen et al. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clinical Cancer Research, v. 6, n. 5, p. 1778-1783, 2000Tradução . . Acesso em: 22 out. 2025.
APA
Ree, A. H., Pacheco, M. M., Tvermyr, M., Fodstad, O., & Brentani, M. M. (2000). Expression of a novel factor, com1, in early tumor progression of breast cancer. Clinical Cancer Research, 6( 5), 1778-1783.
NLM
Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clinical Cancer Research. 2000 ; 6( 5): 1778-1783.[citado 2025 out. 22 ]
Vancouver
Ree AH, Pacheco MM, Tvermyr M, Fodstad O, Brentani MM. Expression of a novel factor, com1, in early tumor progression of breast cancer. Clinical Cancer Research. 2000 ; 6( 5): 1778-1783.[citado 2025 out. 22 ]

Unidades USP

ReP

Filtros

Unidades USP

Departamento

Autores

Autores USP

Ano de publicação

Assuntos

Nome do evento

Indexado em

Afiliação dos autores externos não normalizada